Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma.


Journal

Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955

Informations de publication

Date de publication:
06 2022
Historique:
received: 10 09 2021
revised: 19 12 2021
accepted: 02 01 2022
pubmed: 3 2 2022
medline: 31 5 2022
entrez: 2 2 2022
Statut: ppublish

Résumé

Several guidelines have adopted early integration of palliative intervention (PI) into oncologic care to improve quality of life among patients with advanced malignancies. However, PI utilization patterns and factors associated with its use in metastatic renal cell carcinoma are poorly understood. Using the National Cancer Database (NCDB), we abstracted patients diagnosed with Stage IV RCC from 2004 to 2014 and evaluated the utilization of PI within this cohort. Socioeconomic and clinical factors were compared for patients receiving and not receiving PI for metastatic RCC. Multivariable logistic regression (MLR) models identified factors that were associated with receipt of PI within overall cohort and treatment-based cohorts. We identified 42,014 patients with Stage IV RCC, of which 7,912 patients received PI. From 2004 to 2014, the use of PI minimally increased from 17% to 20% for Stage IV RCC. MLR analysis demonstrated that increased comorbidities, insurance status, higher education status, facility location, care at a comprehensive cancer program or integrated network, sarcomatoid histology, and treatment type significantly increased the likelihood of PI use. Various socioeconomic, clinical, and geographical factors that are associated with use of PI-based on the treatment received for Stage IV RCC. While PI utilization has minimally increased for Stage IV RCC, there are several geographic, socioeconomic, and clinical factors that predict its use among patients with Stage IV RCC in a treatment-specific manner. Taken together, this suggests the need for earlier initiation of PI in a more equitable and systematic fashion among patients with metastatic RCC.

Identifiants

pubmed: 35105510
pii: S1558-7673(22)00001-5
doi: 10.1016/j.clgc.2022.01.001
pmc: PMC9149103
mid: NIHMS1769903
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

296-296.e9

Subventions

Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Références

Am J Hosp Palliat Care. 2020 Feb;37(2):136-141
pubmed: 31337229
Urol Oncol. 2015 Jun;33(6):267.e23-9
pubmed: 25814144
JAMA. 2002 Feb 20;287(7):875-81
pubmed: 11851580
Nat Rev Urol. 2021 Oct;18(10):623-635
pubmed: 34312530
J Natl Compr Canc Netw. 2015 Sep;13(9):1131-8
pubmed: 26358797
Clin Geriatr Med. 2015 Nov;31(4):667-78
pubmed: 26476123
JAMA. 2009 Aug 19;302(7):741-9
pubmed: 19690306
J Palliat Med. 2016 Apr;19(4):360-72
pubmed: 26788621
Anesthesiol Clin. 2006 Mar;24(1):129-44
pubmed: 16487899
Cancer J. 2010 Sep-Oct;16(5):423-35
pubmed: 20890138
J Pain Symptom Manage. 2017 Jun;53(6):1091-1096
pubmed: 28196784
Ann Surg. 2017 Jan;265(1):32-33
pubmed: 27163958
Health Aff (Millwood). 2016 Sep 1;35(9):1690-7
pubmed: 27605652
Health Aff (Millwood). 2011 Mar;30(3):454-63
pubmed: 21383364
J Natl Compr Canc Netw. 2016 Apr;14(4):439-45
pubmed: 27059192
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
J Natl Compr Canc Netw. 2019 Nov 1;17(11):1344-1352
pubmed: 31693981
BJU Int. 2019 Jun;123(6):968-975
pubmed: 30758125
J Pain Symptom Manage. 2018 Apr;55(4):1196-1215.e5
pubmed: 29221845
J Clin Oncol. 2002 Dec 1;20(23):4559-66
pubmed: 12454113
Urol Oncol. 2020 Nov;38(11):854.e1-854.e9
pubmed: 32430252
Crit Care Med. 2015 May;43(5):1102-11
pubmed: 25574794
Am J Hosp Palliat Care. 2019 Sep;36(9):801-806
pubmed: 30808193
Onco Targets Ther. 2014 Feb 27;7:365-74
pubmed: 24600236
Am J Hosp Palliat Care. 2015 Mar;32(2):137-43
pubmed: 24097838
J Palliat Med. 2012 Aug;15(8):923-30
pubmed: 22731514
JAMA Netw Open. 2020 Aug 3;3(8):e2014639
pubmed: 32833020

Auteurs

Hiren V Patel (HV)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Sinae Kim (S)

Division of Biometrics, Rutgers Cancer Institute of New Jersey and Rutgers School of Public Health, New Brunswick, NJ.

Arnav Srivastava (A)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Brian M Shinder (BM)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Joshua Sterling (J)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Biren Saraiya (B)

Division of Medical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Tina M Mayer (TM)

Division of Medical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Saum Ghodoussipour (S)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Thomas L Jang (TL)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Eric A Singer (EA)

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. Electronic address: eric.singer@rutgers.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH